Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis.


Cilli A., Uzer F., Sevinç C., Coşkun F. , Ursavaş A., Öner Ş., ...More

Pulmonary pharmacology & therapeutics, vol.71, pp.102099, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 71
  • Publication Date: 2021
  • Doi Number: 10.1016/j.pupt.2021.102099
  • Title of Journal : Pulmonary pharmacology & therapeutics
  • Page Numbers: pp.102099
  • Keywords: IPF, Nintedanib, Pirfenidone, Switch, ACUTE EXACERBATION, PIRFENIDONE, NINTEDANIB, SAFETY

Abstract

Background: The antifibrotic drugs nintedanib and pirfenidone reduce disease progression in idiopathic pulmonary fibrosis (IPF) and have also shown to improve survival. Switching first-line antifibrotic drug may required in IPF due to disease progression or intolerable adverse effects. The aim of this study was to assess the safety and efficacy of second-line antifibrotic treatment in patients with IPF.